Research Analysts Issue Forecasts for BioLineRx Q1 Earnings

BioLineRx Ltd. (NASDAQ:BLRX) – Equities research analysts at HC Wainwright issued their Q1 2025 earnings estimates for shares of BioLineRx in a research note issued on Monday, March 31st. HC Wainwright analyst J. Pantginis forecasts that the biotechnology company will post earnings of ($0.84) per share for the quarter. HC Wainwright has a “Buy” rating and a $26.00 price objective on the stock. The consensus estimate for BioLineRx’s current full-year earnings is ($5.80) per share. HC Wainwright also issued estimates for BioLineRx’s Q2 2025 earnings at ($0.77) EPS, Q3 2025 earnings at ($0.92) EPS and Q4 2025 earnings at ($0.99) EPS.

A number of other analysts have also recently commented on BLRX. StockNews.com cut BioLineRx from a “hold” rating to a “sell” rating in a research report on Tuesday, March 18th. Jones Trading reaffirmed a “hold” rating on shares of BioLineRx in a report on Wednesday.

BioLineRx Price Performance

Shares of BLRX opened at $3.10 on Wednesday. The company has a debt-to-equity ratio of 2.11, a current ratio of 1.52 and a quick ratio of 1.37. The company’s fifty day moving average price is $3.47 and its 200-day moving average price is $10.57. BioLineRx has a 1-year low of $2.85 and a 1-year high of $35.60. The firm has a market capitalization of $10.32 million, a PE ratio of -0.35 and a beta of 1.39.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in BioLineRx stock. Highbridge Capital Management LLC purchased a new position in shares of BioLineRx Ltd. (NASDAQ:BLRX) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 1,010,012 shares of the biotechnology company’s stock, valued at approximately $215,000. Highbridge Capital Management LLC owned 50.50% of BioLineRx as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 1.56% of the company’s stock.

BioLineRx Company Profile

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.